KBC Securities - Hyloris Pharmaceuticals (HYL) Hyloris Valacyclovir oral suspension deal with Rosemont, appoints new CFO

Report

KBC Securities

Jacob Mekhael

Hyloris Valacyclovir oral suspension deal with Rosemont, appoints new CFO

Hyloris announced an exclusive license and supply agreement with Rosemont Pharmaceuticals for its Valacyclovir oral suspension in the US. In addition, the company appointed a new CFO, Christophe Maréchal, who previously served as CFO and co-CEO of Mithra. We reiterate our € 5 TP and HOLD rating.

09/12/2024 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : ARGXb BB, GLPG NA, HYLb BB

: ARGXb BB, GLPG NA, HYLb BB

23h / 25m 23h / 25m 1 EN

KBC Securities

Hyloris Agreement with Kuvatris could generate a priority review voucher

Hyloris announced the signing of an R&D funding agreement of $ 2m (plus $ 1.6m equity investment) with Kuvatris to support the development and US approval of intravenous (IV) suramin to treat human African trypanosomiasis (HAT). Given the rare nature of HAT, the value of this program lies in its potential to secure a transferable PRV. Recent examples show PRVs being sold for $160m – Hyloris could get just over 50% of net proceeds, if successful. We see this as a creative deal to boost the company's cash position, and update our model assuming such a sale could take place in 2028. This increase...

23h / 31m 23h / 31m 1 EN

KBC Securities

Morning Notes : AED BB, BARb BB, HYLb BB, SOF BB, TINC BB, MRUS US

: AED BB, BARb BB, HYLb BB, SOF BB, TINC BB, MRUS US

June 4, 2025 June 4, 2025 1 EN

argenx European Commission approves Vyvgart SC in CIDP

argenx announced that the European Commission (EC) approved Vyvgart SC for the treatment of adults with progressive or relapsing active CIDP after prior treatment with corticosteroids or immunoglobulins, which comes in line with expectations following the positive CHMP opinion issued in April 2025. We anticipate a steady country by country EU launch, and continue to expect the US to remain the main driver for Vyvgart's commercial launch. We currently estimate approx. $ 1.1bn in peak sales for CIDP in the EU by the mid-2030s vs. $ 3.7bn peak sales globally for the indication. We reiterate our €...

23h / 11m 23h / 11m 1 EN

Jacob Mekhael

Jacob Mekhael

Galapagos Appoints Aaron Cox as new CFO

Galapagos announced the appointment of Aaron Cox as CFO, effective 7 July 2025. Most recently, he served as Executive VP and CFO at Horizon Therapeutics. Aaron replaces Thad Huston, who joined Galapagos as CFO in 2023. With plans to explore strategic options for the cell therapy business, as well as plans to utilise the €3.3b cash (as of 1Q25) to build a new pipeline through business development, Aaron's network and experience in deal making will be key to Galapagos' strategy going forward. We reiterate our € 37 TP and Buy rating.

23h / 15m 23h / 15m 1 EN

Hilde Van Boxstael ... (+3)

Hilde Van Boxstael
Jacob Mekhael
Wim Lewi

Morning Notes : ARGXb BB, GLPG NA, HYLb BB

: ARGXb BB, GLPG NA, HYLb BB

23h / 25m 23h / 25m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Hyloris Valacyclovir oral suspension deal with Rosemont, appoints new CFO

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ARGXb BB, GLPG NA, HYLb BB

Hyloris Agreement with Kuvatris could generate a priority review voucher

Morning Notes : AED BB, BARb BB, HYLb BB, SOF BB, TINC BB, MRUS US

argenx European Commission approves Vyvgart SC in CIDP

Galapagos Appoints Aaron Cox as new CFO

Morning Notes : ARGXb BB, GLPG NA, HYLb BB

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe